Experimental treatments that use the body's own immune system to fight cancer are nothing short of amazing. At the year's biggest scientific conference for cancer drug developers, bluebird bio (NASDAQ: BLUE) showed us that its candidate can prolong the lives of people who had exhausted all available options.Despite the highly positive results released after the bell on Friday, the stock ticked up just a few percentage points on Monday.